Kelly Schick

This profile gathers the share dealings of Kelly Schick in C4 Therapeutics, Inc., where the filings describe the role as senior executive. Over a trading history stretching from 25 May 2022 to 13 February 2026, the count stands at 10 filings.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.

On 18 February 2026 came the latest disclosure, a share grant in C4 Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.